Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a Phase 1b/2, multicenter, open-label, study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD19 and CD20, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Cohort A (CAR-T Naïve): participants who have previously not received CAR-T cell therapy for the treatment of lymphoma.
Cohort B (CAR-T Exposed): participants who have relapsed disease and prior exposure to CAR-T cell therapy for the treatment of lymphoma.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
385 participants in 1 patient group
Loading...
Central trial contact
Study Contact, M.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal